NCT06236425 2026-04-01
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT05614102 2026-03-31
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT02866136 2025-11-24
RETINO2011
Institut Curie
Phase 2 Active not recruiting
NCT07215962 2025-10-14
Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%
Bristol-Myers Squibb
Active not recruiting
NCT04906993 2025-09-09
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Active not recruiting
NCT05607550 2025-06-22
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)
ArriVent BioPharma, Inc.
Phase 3 Active not recruiting
NCT06234748 2025-05-13
ARTHOUSE
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT05338970 2025-01-31
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
Daiichi Sankyo
Phase 3 Active not recruiting
NCT04379739 2023-12-06
Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Active not recruiting